Cygnus, Inc.

University of Utah Research Foundation

Other

Tsung-Min Hsu

Robert V Petersen

Eric J Roos

Don Christy

Han-Chen Lee

Tung Fen Chen

Chia-Ming Chiang

The present invention provides a method for producing an active ingredient for a rivastigmine free base transdermal patch having preparing a rivastigmine free base; and adding an acidic substance to the rivastigmine free base and subjecting the acidic substance and the rivastigmine free base to a mixed reaction to form a mixture having a pH value from 6.0 to 8.5 as the active ingredient; and a rivastigmine free base transdermal patch having a drug layer comprising the active ingredient. The rivastigmine free base transdermal patch has a stable transdermal transmission time equal to or longer than 48 hours and equal to or less than 168 hours. The active ingredient produced by the method and the transdermal patch having the active ingredient allow effective and smooth release of rivastigmine free base and prolongs the release time to meet the clinical application needs.

Method for producing active ingredient for rivastigmine free base transdermal patch and rivastigmine free base transdermal patch comprising the same

A two-phase hydrophilic drug-containing matrix for use in transdermal drug delivery patches in which one phase is a continuous hydrophobic polymer phase which optionally includes a hydrophobic solvent that acts as a skin permeation enhancer and the other phase is a dispersed particulate hydrated inorganic silicate in whose absorbed aqueous phase the drug is dissolved.

Two-phase matrix for sustained release drug delivery device

Prazosin is formulated in solution with a akin permeation enhancer composition of: a sulfhydryl-containing compound, a fatty acid eater, and a polar solvent for transdermal administration to treat hypertension or benign prostatic hypertrophy. The formulation is employed in the form of a skin patch comprising (a) an impermeable backing layer, (b) a reservoir of the prazosin-enhancer solution, (c) a porous support member that retains the solution but is not a permeation barrier to the solution, a peripheral adhesive layer for affixing the patch to the skin, and a release liner layer.

Transdermal formulations for administering prazosin

Matrix-type transdermal drug delivery devices for administering potent steroids such as ethinyl estradiol at a low flux steady-state rate over a multi-day period comprising a laminate of: (a) an occlusive backing layer and (b) a matrix layer of the drug completely dissolved at a loading of below 0.5% by weight in a 2-ethylhexyl acrylate copolymer.

Low flux matrix system for delivering potent drugs transdermally

A percutaneous drug delivery method and enhancement composition are disclosed. The method comprises applying an enzyme preparation containing suitable amounts of non-enzyme permeation enhancers, such as lactam compounds (e.g. 1-substituted-azacycloheptan-2-one), and propylene glycol to a localized area of skin for a predetermined amount of time to enhance that area of skin's permeability to selected drug(s); occluding the area of skin during the application; and then applying the selected drug(s) to the area of skin to allow the drug to penetrate through the skin and into the circulatory system of the animal. Greatly enhanced penetration of chemicals through the skin results from the described treatment.

Percutaneous drug delivery system

A percutaneous drug delivery system, method, and kit are disclosed. The method comprises applying an enzyme preparation to a localized area of skin for a predetermined amount of time to enhance that area of skin's permeability to selected drugs, occluding the area of skin during the application, and then applying the selected drug(s) to the area of skin to allow the drug to penetrate through the skin and into the circulatory system of the animal. Greatly enhanced penetration of chemicals through the skin results from the enzyme treatment.

Growing community of inventors

Union City, CA, United States of America

Tsung-Min Hsu